#USA #Jersey City #Lung Cancer #WallachBeth Capital #bioAffinity Technologies

WallachBeth Capital's Recent Financing for bioAffinity Technologies

On October 8, 2026, WallachBeth Capital LLC, a key player in capital markets services, reported a pivotal financing deal for bioAffinity Technologies, a firm at the forefront of developing innovative, noninvasive solutions for early lung disease detection. This deal marks a significant step for bioAffinity, which aims to enhance its offerings in healthcare solutions.

The financing arrangement, set at approximately $4 million, comes in the form of a registered direct offering, complying with regulations from Nasdaq. bioAffinity will sell shares of its common stock at a price of $6.122 per share. Additionally, the company has arranged for a private placement which will allow it to sell warrants for an aggregate total of 980,072 shares, further solidifying their financial backing.

This initiative is essential for funding the ongoing efforts to launch and market CyPath® Lung, bioAffinity's innovative noninvasive test designed for lung cancer detection. With rising incidents of lung-related health issues globally, the test will provide a critical tool for early diagnosis, potentially saving lives through prompt intervention.

The expected closing date for this financing is around October 9, 2026, pending the completion of necessary closing conditions. WallachBeth Capital is serving as the exclusive placement agent for this transaction, ensuring that the process runs smoothly and efficiently.

The company anticipates that the net proceeds will not only bolster its working capital but also support increasing sales for CyPath® Lung and assist in general corporate initiatives. The significance of this financing cannot be overstated—it represents a substantial investment in the healthcare sector at a time when effective disease detection is paramount.

The common stock and warrants offered are being registered under a “shelf” registration statement previously filed with the U.S. Securities and Exchange Commission (SEC). This enables a streamlined process for securities offerings, allowing bioAffinity to efficiently manage its capital raising needs. By securing such funding through public markets, bioAffinity demonstrates confidence in its growth trajectory and the demand for its products.

In a statement from WallachBeth, it was emphasized that while this financing is a robust step forward for bioAffinity, the company remains focused on executing its strategic plans and ensuring shareholder value. The firm has previously handled numerous transactions in the healthcare sector, positioning itself as a trusted partner for companies looking to expand their financial capabilities.

In today’s fast-evolving healthcare landscape, securing capital efficiently is crucial. As bioAffinity Technologies progresses, it exemplifies how forward-looking companies are reshaping the future of healthcare diagnostics. The insights gained from early detection technologies like CyPath® Lung can lead to better patient outcomes and more tailored interventions, reinforcing the need for ongoing innovation in medical technology.

Looking forward, the financing provided by WallachBeth Capital is more than just a financial transaction; it’s a lifeline that empowers bioAffinity to advance its mission of improving healthcare outcomes. As they continue their journey, stakeholders and investors alike will be observing how this deal enhances their product offerings and market positioning.

In conclusion, WallachBeth’s facilitation of this $4 million financing deal underscores its commitment to fostering growth within the biotechnology realm and reflects the growing importance of innovative healthcare solutions. The future looks promising for bioAffinity Technologies as they pave the way in early disease detection and patient care, backed by this recent investment.